Here is the design of a clinical trial:

Official Title: An Innovative Trial Assessing Donor Sex on Recipient Mortality (iTADS)

Included conditions:
- Red Blood Cell Transfusion

Study Armgroups:
- {'label': 'RBC Transfusion from male donor', 'type': 'ACTIVE_COMPARATOR', 'description': 'For the treatment of anemia', 'interventionNames': ['Other: RBC Transfusion from male donor']}
- {'label': 'RBC Transfusion from female donor', 'type': 'ACTIVE_COMPARATOR', 'description': 'For the treatment of anemia', 'interventionNames': ['Other: RBC Transfusion from female donor']}

Interventions:
- {'type': 'OTHER', 'name': 'RBC Transfusion from male donor', 'description': 'Patients requiring an RBC transfusion for the treatment of anemia will receive products from a male donor at initial and any subsequent hospitalizations during the trial period.', 'armGroupLabels': ['RBC Transfusion from male donor']}
- {'type': 'OTHER', 'name': 'RBC Transfusion from female donor', 'description': 'Patients requiring an RBC transfusion for the treatment of anemia will receive products from a female donor at initial and any subsequent hospitalizations during the trial period.', 'armGroupLabels': ['RBC Transfusion from female donor']}

Primary Outcomes:
- {'measure': 'Survival', 'description': 'Measured from date of first randomization to date of death or end of study 2 years from first patient enrollment.', 'timeFrame': '2 years'}

Please estimate the sample size based on the assumption: 
A two-tailed α of 0.05, a power (1−β) of 0.80, an accrual time of 2 years, median survival time of 5 years, and an 11% non-compliance factor.
Sample size
        The overall mortality rate of hospitalised patients that receive RBC transfusions is high due to patient acuity. In our previous study, after a mean follow-up of 2.3 years (maximum follow-up of 7 years), 43% of patients had died.11 At 1-year follow-up, which is the expected median follow-up time for this study, mortality was 30%, and the median survival was 5 years. From our previous observational work, we expect our intervention to reduce the absolute risk of death by at least 5%.11 We proposed a minimally clinically important difference of 2% (applicable to the entire inpatient and outpatient population). Thus, sample size calculations based on a survival analysis comparing two survival curves using a two-tailed Î± of 0.05 and a 1âÎ² of 0.80, an accrual time of 2 years, median survival time of 5 years, an absolute risk reduction of 2% (30%â28%, corresponding HR of 0.93) and a 11% non-compliance factor require 8850 randomised and transfused patients. Our original estimate was a 3% non-compliance requiring 8000 patients. A revised 11% non-compliance estimate was informed by 1-year aggregate trial data. The 11% non-compliance at the patient level is predominantly due to the allocated donor sex not being available at time of RBC transfusion (first or repeat) or the need for the transfusion service to use expiring units.